{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:54:18Z","timestamp":1791078858238,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2004,10]]},"DOI":"10.1016\/j.jaad.2003.05.010","type":"journal-article","created":{"date-parts":[[2004,9,24]],"date-time":"2004-09-24T23:13:32Z","timestamp":1096067612000},"page":"570-573","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: A case series"],"prefix":"10.1016","volume":"51","author":[{"given":"Fiza","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2003.05.010_bib1","first-page":"58","article-title":"Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies","volume":"27","author":"Foss","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jaad.2003.05.010_bib2","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/archderm.1996.03890350051009","article-title":"Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis","volume":"132","author":"Kim","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2003.05.010_bib3","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archderm.134.8.949","article-title":"Topical corticosteroids for mycosis fungoides. Experience in 79 patients","volume":"134","author":"Zackheim","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2003.05.010_bib4","first-page":"536","article-title":"Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group","volume":"69","author":"Thomsen","year":"1989","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2003.05.010_bib5","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2340\/0001555567232236","article-title":"Oral retinoids in mycosis fungoides and Sezary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group","volume":"67","author":"Molin","year":"1987","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2003.05.010_bib6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2340\/0001555567179182","article-title":"Retinoids and systemic chemotherapy in cases of advanced mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group","volume":"67","author":"Molin","year":"1987","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2003.05.010_bib7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1067\/mjd.2002.121355","article-title":"Practical evaluation and management of cutaneous lymphoma","volume":"46","author":"Fung","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2003.05.010_bib8","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent earlystage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2003.05.010_bib9","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0733-8635(18)30176-1","article-title":"Cytogenetic findings in cell lines from cutaneous T-cell lymphoma","volume":"12","author":"Kaltoft","year":"1994","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2003.05.010_bib10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/0165-4608(95)00118-2","article-title":"Common clonal chromosome aberrations in cytokine-dependent continuous human T-lymphocyte cell lines","volume":"85","author":"Kaltoft","year":"1995","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.jaad.2003.05.010_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0165-4608(94)00192-8","article-title":"Appearance of isochromosome 18q can be associated with in vitro immortalization of human T lymphocytes","volume":"81","author":"Kaltoft","year":"1995","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.jaad.2003.05.010_bib12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/1523-1747.ep12285617","article-title":"Chromosomal abnormalities in cutaneous T-cell lymphoma and in its premalignant conditions as detected by G-banding and interphase cytogenetic methods","volume":"108","author":"Karenko","year":"1997","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2003.05.010_bib13","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/sj.jid.5600444","article-title":"Notable losses at specific regions of chromosomes 10q and 13q in the Sezary syndrome detected by comparative genomic hybridization","volume":"112","author":"Karenko","year":"1999","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2003.05.010_bib14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0165-4608(94)00292-4","article-title":"Chromosome aberrations, spontaneous SCE, and growth kinetics in PHA-stimulated lymphocytes of five cases with Sezary syndrome","volume":"83","author":"Limon","year":"1995","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.jaad.2003.05.010_bib15","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/1523-1747.ep12363378","article-title":"The immune response to class I-associated tumor-specific cutaneous T- cell lymphoma antigens","volume":"107","author":"Berger","year":"1996","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2003.05.010_bib16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1600-0560.1994.tb00250.x","article-title":"Mycosis fungoides skin lesions contain CD8+ tumor-infiltrating lymphocytes expressing an activated, MHC-restricted cytotoxic T- lymphocyte phenotype","volume":"21","author":"Wood","year":"1994","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2003.05.010_bib17","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1172\/JCI117697","article-title":"The cutaneous T cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus-associated disease. A study of 50 patients","volume":"95","author":"Pancake","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2003.05.010_bib18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.7326\/0003-4819-100-2-187","article-title":"Clinical staging for cutaneous T-cell lymphoma","volume":"100","author":"Lamberg","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2003.05.010_bib19","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1096\/fasebj.10.9.8801176","article-title":"A decade of molecular biology of retinoic acid receptors","volume":"10","author":"Chambon","year":"1996","journal-title":"Faseb J"},{"key":"10.1016\/j.jaad.2003.05.010_bib20","first-page":"95","article-title":"Defective DNA repair in humans: clinical and molecular studies of xeroderma pigmentosum","volume":"53","author":"Kraemer","year":"1990","journal-title":"Basic Life Sci"},{"key":"10.1016\/j.jaad.2003.05.010_bib21","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1346-8138.1992.tb03766.x","article-title":"Chemoprevention of skin cancer in xeroderma pigmentosum","volume":"19","author":"Kraemer","year":"1992","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2003.05.010_bib22","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1067\/mjd.2002.124607","article-title":"Optimizing bexarotene therapy for cutaneous T-cell lymphoma","volume":"47","author":"Talpur","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2003.05.010_bib23","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJM199904083401404","article-title":"Central hypothyroidism associated with retinoid X receptor-selective ligands","volume":"340","author":"Sherman","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.05.010_bib24","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced- stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2003.05.010_bib25","first-page":"1234","article-title":"Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action","volume":"8","author":"Zhang","year":"2002","journal-title":"Clin Cancer Res"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962204018705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962204018705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T21:34:57Z","timestamp":1759268097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962204018705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["S0190962204018705"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2003.05.010","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2004,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: A case series","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2003.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}